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Abstract
Aberrant Wnt-signaling caused by mutants of β-catenin, a key regulator of the canonical Wnt-
signaling pathway, is frequently detected in cancer. Only recently, it was suggested that in
hepatocellular carcinoma (HCC) the expression of the target gene glutamine synthetase (GS) is a
highly reliable marker for the identification of β-catenin mutations. In order to prove this
hypothesis, 52 samples from human hepatocellular carcinomas were analysed for the activation of
β-catenin and the expression of GS. In total, 45 samples stained positive for cytoplasmic/nuclear β-
catenin. A strong correlation between expression of GS and activated β-catenin (100% of nuclear
and 84% of cytosolic) was found. However, among 35 GS positive tumors that were analysed for
β-catenin mutations no mutations were detected in 25 GS-positive carcinomas although 24 out of
the 25 carcinomas exhibited at least abnormal expression of β-catenin. Since the mutational analysis
identified 9 different point mutations of the β-catenin gene including the rare mutation H36P and
the yet unknown mutation P44A it was asked whether these mutations may differently effect β-
catenin target genes. Therefore, expression plasmids for different mutations were constructed and
cotransfected with the TOP-flash luciferase reporter and a reporter carrying the GS-5'-enhancer.
The experiments confirmed that there are differences between different β-catenin target
sequences and different β-catenin mutations. In addition, the failure that the endogenous
expression of GS in GS-negative cells was not induced by the transient transfection experiment
indicated that the effect of β-catenin on the GS-5'-enhancer is only one aspect of gene activation
induced by β-catenin.
Background
Hepatocellular carcinoma (HCC) is the most frequent
cancer worldwide (for review see [1,2]). During the last
years it became obvious that active Wnt-signaling as char-
acterized by the presence of nuclear/cytosolic β-catenin
highly correlates with the occurrence of HCC in animal
models and in human patients [3-6]. Under normal con-
ditions the activated (nuclear) form of β-catenin is a tran-
scriptional activator mainly involved in the regulation of
cell proliferation, differentiation and stem cell mainte-
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nance [7-9]. As a transcriptional regulator β-catenin inter-
acts with members from the LEF-1/TCF transcription
factor family, probably by removal of co-repressors like
groucho [10-12]. It should be noted that LEF-1/TCF is an
architectural transcription factor that upon binding to its
target sequence together with corepressors and in the
absence of β-catenin inhibits expression.
In differentiated, non-proliferating cells, β-catenin is asso-
ciated with membrane bound E-cadherin [13] and non-
bound molecules are quickly removed from the cytosol in
the absence of Wnt-signaling, thereby preventing its trans-
location to the nucleus. This is accomplished by a mul-
tienzyme complex that binds cytosolic β-catenin. When
bound to the complex β-catenin is phosphorylated by
active glycogen synthase kinase 3β(GSK3β), then labelled
by ubiquitinylation and finally degradated by the protea-
some. The complex, in addition to GSK3β, contains other
proteins like Axin1, Casein Kinase Iα (CKIα) and APC
(Adenomatous Polyposis Coli protein) (for review see
[14]). Although mutations in each of the components of
the complex may cause abnormal cytosolic stabilization
of β-catenin, mutations of the β-catenin gene itself appear
to be the most common cause for stabilization in patho-
logical situations. These mutations usually affect residues
at position 33 (S), 37 (S), 41 (T) or 45 (S) located in exon
3 of the human β-catenin gene that are the targets of prim-
ing phosphorylation by CKIα (S45) or subsequent phos-
phorylation by GSK3β (S33, S37 and S41). Activation of
β-catenin finally leads to the transcriptional activation of
a variety of genes [15]. However, not much is known
about the role of specific genes activated with regard to
their role in tumor development. On the other hand,
glutamine synthetase (GS), one of the enzymes identified
to be regulated by nuclear β-catenin, may be a candidate
that contributes to enhanced malignancy of HCCs
[16,17]. In fact, Osada et al. demonstrated that GS expres-
sion may enhance the metastatic potential in HCC, and
that GS immunostaining identifies HCC patients with a
high risk for disease recurrence after curative hepatectomy
[18]. In the intact liver, GS is confined to a small popula-
tion of hepatocytes located around the hepatic terminal
venules and is regulated in a highly complex manner [19].
With regard to hepatocyte specific expression, several reg-
ulatory elements have been described, including 5'-
upstream elements [20-22] as well as intronic elements
[23,24]. Recently published experiments identified a
putative binding site for members of the LEF-1/TCF tran-
scription factor family in the main 5'-enhancer that may
be responsible for activation of transcription by activated
β-catenin [22]. However, it is not known whether the 5'-
enhancer does mediate enhancement of expression in the
presence of activated β-catenin. Therefore, we investigated
human HCCs for activated β-catenin and specific expres-
sion of GS and we identified different mutations of exon
3 of the β-catenin gene. Finally, we were able to demon-
strate that different mutations of β-catenin are able to acti-
vate expression from reporter genes with the 5'-enhancer
of the GS gene.
Results
Immunohistochemical detection of β-catenin and 
glutamine synthetase in hepatocellular carcinomas 
(HCCs)
In a first series of experiments 52 human tumor samples
were analysed for the expression of GS and β-catenin.
Immunohistochemistry identified β-catenin positive
nuclei in 13 specimens (e.g. Fig. 1A/D). Cytoplasmic but
no obvious nuclear staining was detected in 32 tumors
(e.g. Fig. 1C) and normal membranous expression of β-
catenin was observed in 7 HCCs (e.g. Fig. 1B). All tumors
that exhibited a nuclear presence of β-catenin were
expressing GS (e.g. Fig. 1D/E). In contrast, the cytoplasmic
presence of β-catenin was associated with GS expression
in 84% of the HCCs but still 43% of the HCCs with nor-
mal membranous β-catenin staining were GS positive
(Fig. 2).
Analysis of β-catenin mutations present in GS-positive 
hepatocellular carcinomas
Next it was asked, whether the phenotypes observed by
immunohistochemistry were associated with certain
mutations of the β-catenin gene (CTNNB1). Therefore,
DNA was extracted from samples, amplified by PCR and
sequenced. It was possible to amplify DNA from 40 sam-
ples out of the 52 specimens that were investigated by
immunohistochemistry. The analysis revealed 9 different
point mutations of the CTNNB1  gene in 10 (25%)
patients (Table 1). All mutations affected the degradation
box in exon 3 of β-catenin. In 4 cases residues for GSK-3β
phosphorylation were changed, namely to cysteine
(S33C, S37C), to phenylalanine (S37F) or to alanine
(T41A). Furthermore, the mutations I35S and H36P (two
cases) were identified within the β-TrCP recognition
sequence. Serine at position 45 was replaced by proline in
two cases and to phenylalanine in 1 case. One of the
patients with S45P exhibited a mutation of proline 44 to
alanine in addition. In 8 out of the 10 samples with muta-
tions we observed nuclear accumulation of β-catenin. The
two cases of GS positive tumors without definite nuclear
staining for β-catenin (P44A and S45P) at least showed a
cytoplasmic presence of β-catenin. Therefore, it is obvious
that every specimen with mutations of the CTNNB1 gene
exhibited expression of GS. However, no mutations
within the degradation box in exon 3 of the β-catenin
gene were found in 25 GS positive tumors, 20 of them
expressing cytoplasmic, 4 nuclear and 1 normal, membra-
nous β-catenin (for complete set of data see Table 2).Molecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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Examples of β-catenin phenotypes detected in human hepatocellular carcinomas Figure 1
Examples of β-catenin phenotypes detected in human hepatocellular carcinomas. A: Magnification of the squared 
area seen in 'D' with β-catenin located in the cytoplasm and also in several nuclei (arrowheads). B: Tumor with normal confine-
ment of β-catenin to the cell membrane and C: cytoplasmic staining of β-catenin without detectable expression in the nuclei. D 
and E: serial sections of an HCC expressing glutamine synthetase (E) and nuclear β-catenin (D). Original magnification: 400× 
(A, B, C) and 100× (D, E). The mutation of β-catenin in the serial sections was S33C.
Table 1: β-catenin mutations detected in HCCs. Indicated is the number of the codon affected and the resulting amino acid change as 
well as the phenotype observed by immunohistochemistry with regard to presence of β-catenin (cytoplasmic/nuclear) and GS-
expression (GS).
Patient number Codon Mutation Aminoacid β-Cat cytoplasmic β-Cat nuclear GS
20071/2,3,-00 33 TCT > TGT S>C + + +
30600/4-05 35 ATC>AGC I>S + + +
334/2-02
24138/E-01
36 CAT>CCT H>P + + +
14865/2-05 37 TCT>TGT S>C + + +
4836/3-05 37 TCT>TTT S>F + + +
21217-00 41 ACC>GCC T>A + + +
6700/2.3.-05 44 CCT>GCT P>A + - +
6700/2.3.-05
29923/B-03
45 TCT>CCT S>P + - +
28356/2-05 45 TCT>TTT S>F + + +Molecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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Since activation of β-catenin can also be caused by muta-
tions in other genes of the Wnt-signaling pathway, the
APC-, the GSK-3β- and the β-catenin-binding domains of
the AXIN1 gene of 18 patients were analysed. In fact, two
samples were identified with a 3 bp deletion starting with
nucleotide 289 deleting a tyrosine at position 97 within
the APC-binding site of Axin1 (AF009674). However,
only one of the samples expressed cytosolic β-catenin that
interestingly also expressed GS. The other tumor sample
showed membranous β-catenin and no obvious GS
expression.
Influence of β-Catenin mutations detected in 
hepatocellular carcinomas on the expression of reporter 
genes with the GS-5'-enhancer
Since we wondered whether the mutations of β-catenin
detected in samples of human hepatocellular carcinomas
are directly responsible for the activation of Wnt-target
genes and especially for the expression of GS, plasmids
were developed in order to express the mutated forms of
β-Catenin in transfected cells. Therefore, we constructed
expression plasmids, including ones for the rare mutation
H36P and the non-described mutation P44A as well as
expression plasmids for S45F and S45P. Additionally,
reporter gene expression in the presence of these new con-
structs was compared to expression in the presence of
plasmids carrying a truncated β-catenin, lacking the N-ter-
minal phosphorylation sites ('pBatem') and a β-catenin
with all four phosphorylation sites mutated to alanine,
designated 'pCS2' (S33A, S37A, T41A and S45A). In order
to normalize for endogeneous activity of Wnt-signaling
the control plasmid 'bCATa' was used. Firstly, the reporter
genes were cotransfected into HuH7 cells together with
the 'TOP-flash' plasmid that harbours six LEF-1/TCF-bind-
ing sites. As control the same plasmids were cotransfected
with Fop-flash that is equal to 'TOP-flash' but does not
contain the LEF-1/TCF-binding sites. Forty eight hours
after transfection cells were harvested and luciferase activ-
ity was determined. The factor of enhancement was deter-
mined by comparing 'TOP-flash' expression with
expression from 'FOP-flash' for each of the different
expression plasmids used. The result of the experiment is
presented in Fig. 3. As can be seen, 'TOP-flash' and 'FOP-
flash' differ in their level of expression even in the negative
control (transfection with 'bCATa') by a factor of almost
5. This actually indicates that there is some endogenous
activity of Wnt-signaling present in the HuH7 cells used in
the experiment. However, in the presence of activating β-
catenin mutations the difference between 'TOP-flash' and
'FOP-flash' becomes strongly pronounced. The highest
response was obtained with the mutations S45F and the
rare H36P, whereas gene activation of the truncated β-cat-
enin (pBatem) was comparable to P44A, the newly found
mutation. The substitution of all phosphorylation sites
(pCS2) was comparable to S45P. Therefore the β-catenin
mutations detected in GS-positive HCCs are regulators of
the LEF-1/TCF target sequences of the TOP-flash plasmid.
However, the question remained whether they are also
Correlation between expression of GS and the phenotype of  β-catenin expression Figure 2
Correlation between expression of GS and the phe-
notype of β-catenin expression. The %age of GS-
expressing tumors with nuclear (N), cytosolic (C) and nor-
mal membranous (M) β-catenin expression is indicated. 
Numbers on top indicate the total amount of HCCs in each 
group.
Table 2: Correlation between mutations of the β-catenin gene, the location of β-catenin and the expression of GS. In the table all cases 
analysed by immunohistochemistry are listed. +GS: GS-positive;-GS: GS-negative; +M: with mutation;-M: without mutation; n.d.: 
Mutations were not determined due to lack of DNA; C: cytoplasmic, N: nuclear and M: normal membranous expression of β-catenin.
+GS +M +GS -M +GS n.d. -GS +M -GS -M -GS n.d.
C2 2 0 4024
N841000
M012031Molecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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able to activate GS via its 5'-enhancer that was previously
shown to harbour an active LEF-1/TCF-binding site. To
resolve this question an experiment was performed with a
reporter gene containing the GS-5'-enhancer ('HIII/
EV_pT81'). This reporter gene carries the HindIII/EcoRV-
fragment from the rat GS gene encompassing the DNA
sequence from position -2516 to -2146 upstream from the
transcriptional start point that includes the 5'-enhancer
complex [22]. HuH7 cells were cotransfected with this
reporter gene or with the control vector pT81 containing
only the reduced HSV-tk-promoter (used for the construc-
tion of 'HIII/EV_pT81'). For cotransfection, again, the
expression plasmids for the different variants of β-catenin
were used. The factors of enhancement presented in Fig. 4
were determined by comparing expression of 'pT81' to
'HIII/EV_pT81' in the presence of the different expression
plasmids for the β-catenin variants. The factor of enhance-
ment of expression of 'HIII/EV_pT81' compared to 'pT81'
in the presence of the reference control plasmid 'bCATa'
(Fig. 4) again indicates the HuH7 specific background
activity of Wnt-signaling. which in this experiment was ~6
fold. However, all other cotransfections with the other β-
catenin forms including the ones identified in the study
presented, led to a factor of enhancement comparable to
that obtained with the Top-flash system. In fact, only
enhancement mediated by the mutation S45F was slightly
but significantly higher than the other ones. This experi-
ment for the first time clearly demonstrates that the
mutant variants of β-catenin do directly target the GS-5'-
enhancer and appear to be responsible for enhanced
expression of GS in the presence of mutated forms of β-
catenin.
Since reporter gene experiments clearly demonstrated that
the GS-5' enhancer is a target for enhancement of expres-
sion mediated by mutated β-catenin, it was asked how the
expression of endogenous GS is influenced by β-catenin
mutants. Therefore, the expression plasmid for β-catenin
with S45F that proofed to be most effective in reporter
gene experiments was transfected into HuH7 cells and GS
activity was determined. However, we were not able to
detect any enhanced expression of GS between 24 and
120 hours after transfection (data not shown). The same
result was obtained with cells from other lines as FAO or
primary rat hepatocytes, no matter whether overall GS-
activity of the transfected culture was determined or single
cell determination of GS expression using specific anti-
bodies was employed (data not shown).
Effect of different mutations of β-catenin on the expression  of a reporter gene with the main 5'-enhancer of GS Figure 4
Effect of different mutations of β-catenin on the 
expression of a reporter gene with the main 5'-
enhancer of GS. Cells from the cell-line HuH7 were trans-
fected with the reporter gene 'HIII/EV_pT81' containing the 
main GS 5'-enhancer together with different expression plas-
mids for β-catenin forms (compare legend to Fig. 3). Expres-
sion was compared to expression from pT81 in order to 
determine the factor of enhancement mediated by the 
mutants.
Effect of different mutations of β-catenin on the expression  of the reporter gene 'TOP-flash' Figure 3
Effect of different mutations of β-catenin on the 
expression of the reporter gene 'TOP-flash'. Cells 
from the cell-line HuH7 were transfected with the reporter 
gene 'TOP-flash' harbouring LEF-1/TCF binding sites for β-
catenin and the corresponding 'FOP-flash' without these 
sites. Each of the two reporters was cotransfected with sev-
eral expression plasmids for different β-catenin forms: The 
construct 'bCATa' as a control not expressing any functional 
protein, the vector 'pBatem' expressing a truncated β-cat-
enin, 'pCS2', expressing a form with a mutation of all N-ter-
minal phosphorylation sites to alanine and in addition 
plasmids with mutations found in human HCCs: H36P, P44A, 
S45F and S45P. The expression from each co-transfection 
with 'TOP-flash' was compared to cotransfection with 'FOP-
flash' in order to determine the factor of enhancement medi-
ated by the mutants.Molecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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Discussion
GS expression, β-catenin expression and mutations of β-
catenin in HCC
The nuclear and/or cytoplasmic stabilization of β-catenin
is recognized as a hallmark of an altered Wnt/β-catenin
pathway [25]. At the time the present study was initiated,
mouse models already had demonstrated a close correla-
tion between the activation of β-catenin and the aberrant
expression of GS in hepatocellular carcinomas [16,17].
Since it was asked whether this may also be the case in
human hepatocellular carcinomas 52 tumor samples
from patients were analysed for the coexpression of acti-
vated β-catenin as exemplified by the nuclear or the cyto-
plasmatic presence of the protein and expression of GS.
Only recently, two equivalent studies were published by
Zucman-Rossi et al. [26] and by Audard et al. [27].
Although some observations from our study are in agree-
ment with these investigations there are differences that
need to be discussed. For instance, Audard et al. report
that 37% of tumors with β-catenin mutations they exam-
ined were without cytosolic/nuclear staining of β-catenin.
However, in our study every mutation (10 patients)
resulted in nuclear (8 patients) or cytosolic (2 patients)
staining of β-catenin. More importantly, although the
nuclear/cytoplasmic presence of β-catenin highly corre-
lates with aberrant expression of GS the inverse relation-
ship was not true, since we observed a number of cases of
strong aberrant GS expression in the clear absence of β-
catenin mutations. Therefore, our data does not support
the opinion of Audard et al. that GS immunostaining is a
trustable indicator of β-catenin mutations, although aber-
rant expression of β-catenin highly correlates with expres-
sion of GS. In addition, a strict interpretation of the data
from Audard et al. would be that GS is not activated by
wild-type β-catenin but only by mutant forms. However,
this is in contrast to our investigation as well as that of
Zucman-Rossi et al. who detected aberrant staining in sev-
eral hepatocellular carcinomas also in the absence of
mutations of β-catenin. At this point it should be noted
that the mouse models of Colnot et al. [28] and of Ben-
hamouche et al. [29] clearly indicate that the aberrant
expression of non-mutated β-catenin caused by a loss of
APC is accompanied by aberrant expression of GS.
With regard to mutations of the Axin1 gene we have iden-
tified a 3 bp deletion affecting the tyrosine at position 97
within the APC-binding site of Axin1 in two out of 18 ana-
lysed HCC. Only one of these two samples expressed
cytosolic β-catenin and GS and the other did not express
β-catenin nor GS. Therefore, loss of Axin1 function does
not necessarily cause aberrant expression of β-catenin and
GS in agreement with Zucman-Rossi et al. [26].
In conclusion, the diagnostic value of GS expression for
the detection of β-catenin mutations or even for Wnt-sig-
naling is doubtful, since tumors can be detected that
express GS even in the absence of aberrant β-catenin
expression and not every tumor with cytosolic β-catenin
expresses GS.
How is GS activated by β-catenin at the molecular level?
One important question of the work presented was to
analyse how mutations of β-catenin are able to influence
expression of GS. The cell line HuH7 was chosen for trans-
fection experiments, since it had a low Wnt-signaling
background activity compared with cells from the lines
FAO or HepG2 (data not shown). Reporter genes with the
GS-5'-enhancer and the 'TOP-flash' reporter plasmid were
transfected together with expression plasmids for different
mutated β-catenins into HuH7 cells. The strongest factor
of enhancement (~17 fold with the GS-5' enhancer and
~22 fold with 'TOP-flash') was observed in the presence of
the mutation S45F. Serine 45 is known as the priming
position since its phosphorylation by casein kinase 1
(CKI1) is necessary for the subsequent phosphorylation
of T41, S37 und S33 by glycogen synthase kinase 3β
(GSK3β) that finally leads to ubiquitinylation and degra-
dation of β-catenin by the proteasome. Therefore, from
this point of view it was not surprising that a mutation of
this position caused the highest effect. However, S45P
affecting the same priming position was less effective in
both, 'TOP-flash' and the GS-5'-reporter. Interestingly,
this mutation did not result in nuclear staining for β-cat-
enin (Table 1). With regard to the GS-5' enhancer,
enhancement of expression was more or less equal
between the mutations S45P, P44A, H36P, pCS2 (all
phosphorylation sites mutated to alanin) or pBatem (N-
terminal region with all phosphorylation sites deleted).
Interestingly, the rare mutation H36P is a strong mutation
although it does not directly involve a phosphorylation
site. However, it is close to the phosphorylation site S37
and the introduction of a proline in close proximity may
alter the structure of the protein in a way that interferes
with phosphorylation. The same may apply for P44A, the
new mutation detected in this work, that also does not
directly affect a phosphorylation site. At this point it may
be interesting to note that P44A appears to be a rather rare
mutant since it was not found among the 60 mutants
identified by Audard et al. When the effects of different
mutations on 'TOP-flash' and the reporter with the GS-5'
enhancer were compared, some interesting differences
could be observed. For example the rare mutation H36P
caused the same strong fold-enhancement of 'TOP-flash'
expression as S45F. However, the reporter with the GS-5'
enhancer responded more strongly to S45F than H36P. In
addition, the mutation P44A enhanced expression from
'TOP-flash' not as strong as H36P while in case of the
reporter with the GS-5' enhancer both mutations were
equally effective. These different responses of 'TOP-flash'
and the GS-5' enhancer to different β-catenin mutantsMolecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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may indicate that regulation of GS by mutant β-catenin
may be different to regulation of typical LEF-1/TCF target
sequences as presented by 'TOP-flash'. This is an interest-
ing aspect that should be investigated in future experi-
ments.
The failure to obtain enhanced expression of endogenous
GS after transfection of the β-catenin mutant S45F which
is in sharp contrast to the response of the GS reporter con-
struct may highlight another important aspect of GS
expression in normal and neoplastic liver tissue. Previous
work from our laboratory [19] has emphasized that
expression of this enzyme is mainly controlled by mecha-
nisms that silence expression in GS negative hepatocytes.
Two possibilities which might work independently or in
coordination need to be discussed. Firstly, as already
noted above the factor LEF-1/TCF upon which β-catenin
exhibits its influence on gene transcription is an architec-
tural factor that in the absence of β-catenin represses the
transcription of target genes [10]. Thus, the nuclear pres-
ence of β-catenin may remove LEF-1/TCF from its inhibi-
tory position and GS can be expressed. Secondly, it was
demonstrated that the negative transcription factor
GSSEr-BP (glutamine synthetase silencer binding protein
from rat – binding protein) that interacts with a silencer
located in the first intron of the endogenous GS gene [30]
is able to prevent every positive influence from the 5'-
enhancer on gene expression in reporter genes ([23] and
Gaunitz unpublished data). In normal hepatocytes as well
as in tumour cells activation of GS (by β-catenin) is not
possible as long as the silencer binding protein is present.
Therefore, the interesting question remains to be resolved
how this negative factor or its influence is removed or
inhibited by β-catenin (Wnt-signaling).
Methods
Chemicals
All chemicals used were of analytical grade and if not
stated otherwise were purchased from Sigma
(Taufkirchen, Germany).
Tumor samples
We analysed 52 samples of HCC from patients who had
undergone operations at the Uniklinik Leipzig between
1999 and 2005. All patients provided written informed
consent according to the German laws as confirmed by
the local committee. After surgery the material was frozen
in liquid nitrogen and kept at -80°C until use. Sections
from each specimen were examined by a pathologist and
classified as HCC.
Immunohistochemical analysis
β-catenin detection
The surgically resected HCC specimens were fixed in 10%
buffered paraformaldehyde and embedded in paraffin
according to standard protocols. Analysis of β-catenin and
GS expression was performed on serial sections (4 μm)
from each tumor. After deparaffinization and rehydrata-
tion antigen retrieval was applied by microwaving (3 × 5
min) in citrate buffer (0.01 M sodium citrate, pH 6.0). The
endogenous peroxidase was destroyed by hydrogen per-
oxide (3% in TBS (0.01 M Tris Base, 0.9% NaCl, pH 7.6))
and incubated for 10 min. Slides were then immersed in a
solution with 0.05% avidin and 0.01% biotin (10 min)
and finally incubated for 30 min in 5% goat serum
(Sigma-Aldrich, Steinheim, Germany) in order to block
unspecific signals. As primary antibody a β-catenin mon-
oclonal antibody (ab610153, Transduction Laboratories,
Lexington, KY) was used at a dilution of 1:90, incubated
overnight at 4°C. After washing with TBS, the slides were
incubated with a goat anti-mouse IgG-Fc-Biotin
(abAP127B, Chemicon, USA) antibody diluted 1:1000,
washed again in TBS, and incubated with POD-conju-
gated Extravidin (abE2886, Sigma-Aldrich, Steinheim,
Germany) for 30 min. Subsequently, a POD staining with
3,3'-Diaminobenziden (DAB) (Sigma-Aldrich, Steinheim,
Germany) for 7 min according to manufacturer's instruc-
tions was performed. After counterstaining with aqueous
hematoxylin the dehydrated slides were covered in Roti-
Histokitt (Roth, Karlsruhe, Germany).
Glutamine synthetase detection
Detection of glutamine synthetase was performed with
the following modifications to the protocol for β-catenin:
The deparaffinized and rehydrated sections were treated
with 3% hydrogen peroxide and 10% goat serum. The anti
GS monoclonal antibody (ab610517, Transduction Labo-
ratories, Lexington, KY) used was diluted 1:1000 and
incubated overnight at 4°C. The secondary POD-conju-
gated goat anti mouse IgG-FAB antibody (abA3682,
Sigma-Aldrich, Steinheim, Germany) was applied at a
dilution of 1:150 and incubated for 90 min. After washing
the antibody reaction was visualized with DAB as sub-
strate. A counterstaining was performed with aqueous
hematoxylin before dehydration and covering using the
Roti-Histokitt.
DNA Analysis
For the isolation of DNA, 25 mg tumor tissue were used
according to manufacturer's instructions (DNeasy®Tissue
Kit, QIAGEN, Düsseldorf, Germany). The DNA sequence
positions of the β-catenin and Axin1 genes were derived
from NCBI reference sequences NM001904 and
AF009674, respectively. To screen for mutations in the β-
catenin gene (codons 5–79 of exon 3) and the Axin1 gene
(codons 25–258; 378–508), genomic DNA was amplified
by PCR using the following primer pair for β-catenin:
'βCAT exon 3 up' (5'-CAAT GGG TCA TAT CAC AGA TTC
TT-3')/'βCAT exon 3 down' (5'-TCT CTT TTC TTC ACC
ACA ACA TTT-3') and 8 pairs for the Axin1 gene: 'Axin 2/Molecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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1 for' (5'-TGG TTT CAA CAG GAC AGA TTG-3') and 'Axin
2/1 rev' (5'-TCC CGG AGC AGA AAC TGT AG-3'); 'Axin 2/
2 for' (5'-TAT CCA AGA GCA GGG TTT CC-3') and 'Axin
2/2 rev' (5'-GGC TTA TCC CAT CTT GGT CA-3'); 'Axin 2/
3 for' (5'-GAG ACT TCG ACG GCC ACT C-3') and 'Axin 2/
3 rev' (5'-TTC TCC TCG TTC GAG TCA CA-3'); 'Axin 2/4
for' (5'-GAG TCA CTG CAT TCC CTG CT-3') and 'Axin 2/
4 rev' (5'-CTG GTA AAA CAT GGC AGG AT-3'); 'Axin 2/5
for' (5'-CTG GCG AGA GCC ATC TAC C-3') and 'Axin 2/5
rev' (5'-TAC AGA CTT TGG GGC TCT CC-3'); 'Axin 4 for'
(5'-GGG GCC AGG AGC TCT ATT-3') and 'Axin 4 rev' (5'-
TAG AGG TAA GCC TGG CTC GT-3'); 'Axin 5 for' (5'-CGC
TCT TTC CCT TCA CAA AG-3') and 'Axin 5rev' (5'-CCC
CAT GAA GAA CAT CAG GA-3'); 'Axin 6/1 for' (5'-TGC
TTT TTG TTT TCC CCA AG-3') and 'Axin 6/1 rev' (5'-CAG
GAT GCT CTC AGG GTT CT-3').
PCR was performed according to manufacturer's sugges-
tions (Taq PCR Core Kit, Qiagen) using 100 ng of
genomic DNA and 15 pmol of each primer. Cycle condi-
tions were: 94°C for 30 s for denaturation and 55°C for
40 s for hybridization. Elongation was done at 72°C for
45 s. The enzyme was initially activated by denaturation
at 95°C for 3 min and final extension was performed at
72°C for 10 min. The PCR products were checked on
standard agarose gels and purified before they were
sequenced.
Cycle sequencing was performed at the IZKF Core Unit
Leipzig using the ABI PRISM Dye Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems).
Sequencing products were applied to an ABI prism 3100
Genetic Analyser.
Expression plasmids for mutant forms of β-Catenin
The plasmid 'pCS2', containing the human β-catenin
sequence with alanine substitutions at S33, S37, T41 and
S45, was kindly provided from Dr. Kemler (Freiburg) and
the plasmid designated 'pBatem' containing an N-termi-
nal truncated version of β-catenin missing all phosphor-
ylation sites was kindly received from Dr. Hülsken
(Berlin). The plasmid 'βCATa' that was used in some
experiments as control was originally constructed as a vec-
tor for the production of an anti-sense RNA for β-Catenin
by introducing the β-Catenin coding region in an inverse
orientation. However, this plasmid was shown to be una-
ble to prevent Wnt-signaling by knocking-out endogene-
ous  β-Catenin mRNA and we therefore used it for
normalisation in cotransfection experiments since it has
almost the same size as the expression plasmid used in
these experiments.
Expression plasmids with point mutations were con-
structed by the introduction of these mutations by site-
directed mutagenesis (Gene TailorTM Mutagenesis Sys-
tem, Invitrogen, Karlsruhe, Germany) according to the
instructions of the manufacturer. The plasmid
'βCAT_TOTsense', containing the complete coding region
for β-catenin under the control of a CMV-promoter was
used as a template. The following primer pairs were used
to generate the mutant β-catenin plasmids: 'H36P for' (5'-
CTT ACC TGG ACT CTG GAA TCC CTT CTG GTG CCA-3')
and 'H36P rev' (5'-GAT TCC AGA GTC CAG GTA AGA
CTG TTG CTG-3'); 'P44A for' (5'-TCT GGT GGC ACC ACC
ACA GCT GCT TCC CTG AGT-3') and 'P44A rev' (5'-ACC
TTA GGT AAG ACC ACG GTG GTG GTG TCG-3'); 'S45F
for' (5'-GTG CCA CCA CCA CAG CTC CTT TCC TGA GTG
GCA-3') and 'S45F rev' (5'-AGG AGC TGT GGT GGT GGC
ACC AGA ATG GAT-3'); 'S45P for' (5'-GTG CCA CCA CCA
CAG CTC CTC CCC TGA GTG GCA-3') and 'S45P rev' (5'-
AGG AGC TGT GGT GGT GGC ACC AGA ATG GAT-3').
The mutant β-catenin constructs were verified by restric-
tion enzyme analysis and sequencing using the primer
'Mut_Control 1' (5'-TGC CCT CAT CTA GCG TCT CA-3').
Cell lines
Cells from the line HuH7 received a DMEM medium
(containing 1 g/l glucose (PAA, Cölbe, Germany)) supple-
mented with 10% fetal calf serum (PAA, Cölbe, Ger-
many), 2 mmol/L glutamine and antibiotics. The cells
were cultured at 37°C and 90% humidity, in an atmos-
phere containing 5% CO2. One day after seeding, the
medium was removed and fresh medium was added.
Reporter Genes
The reporter gene with the GS-5'region located between a
HindIII site and an EcoRV site (HIII/EVpT81) controlling
a reduced herpes simplex thymidine kinase promoter has
already been described [20]. This sequence emcompasses
the 5'-GS sequence from position -2520 to -2146
upstream from the transcriptional start point. The TCF
reporter gene kit containing the plasmids TOP-flash and
FOP-flash were purchased from Upstate Biotechnology
(Lake Placid, NY).
Transfection Experiments
For transfection HuH7 cells were cultivated at 0.25 × 106
cells per well in 6-well plates in 1.5 ml medium. Twenty
four hours after the start of the culture, transfection was
performed using the cationic lipid formulation Unifectin-
56 (Unifect Group, Moscow, Russia) according to the
manufacturer's instruction. Cells in 6-well plates were
transfected with 0.5 μg DNA per well. Forty eight hours
after transfection cells from 6-well plates were washed
twice with Hank's solution (137 mmol/L NaCl, 5.4
mmol/L KCl, 0.4 mmol/L MgSO4 × 7H2O, 0.5 mmol/L
MgCl2 × 6H2O, 0.35 mmol/L Na2HPO4 × 2H2O, 0.44
mmol/L KH2PO4, 2 mmol/L HEPES, pH 7.4), lysed in 100
μl of lysis buffer (77 mmol/L K2HPO4, 23 mmol/LMolecular Cancer 2008, 7:21 http://www.molecular-cancer.com/content/7/1/21
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KH2PO4, 0,2% Triton X-100, 1 mmol/L dithiothreitol, ph
7.8) and collected with a rubber policeman. Luciferase
measurement was performed as described [31] using a
Multilabel-Reader (Mithras LB 940, Berthold Technolo-
gies, Bad Wildbad, Germany).
Abbreviations
GS: glutamine synthetase, HCC: hepatocellular carci-
noma, TBS: Tris buffered saline, POD: peroxidase, LEF-1/
TCF: lymphoid enhancer factor-1/T-cell factor, Wnt: wing-
less-type MMTV integration site family member, GSSEr-
BP: glutamine synthetase silencer element from the rat-
binding protein.
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